China-based Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to advance a first-in-class novel molecule for idiopathic pulmonary fibrosis. Simcere will fund the exploratory research program, with an embedded option to in-license the molecule and acquire 100% of global commercial rights upon successful completion of the research phase. Financial terms, including the quantum of research funding and any milestone or royalty economics, were not disclosed.
The program will be conducted within Stanford Medicine’s Innovative Medicines Accelerator, led jointly by Chaitan Khosla, PhD — a professor of chemistry and chemical engineering and director of the Accelerator with expertise in lysosome-targeting chimera (LYTAC)-related technologies — and Cui Bianxiao, PhD, a chemistry professor and specialist in fibrosis-related targets. The molecule’s precise mechanism has not been disclosed, though the involvement of LYTAC-related expertise suggests a targeted protein degradation or clearance approach relevant to fibrotic pathology. The program remains at the exploratory research stage, with no clinical trial identifier assigned.
The deal is structured as a research option-to-license, with Simcere securing 100% of global rights upon exercise. No territorial carve-outs, co-promotion rights, or equity components were referenced. The absence of a disclosed headline value is consistent with the pre-clinical stage of the collaboration, where research funding commitments in academic-industry agreements are routinely kept confidential.
This is the second research collaboration between Simcere and Stanford Medicine’s Innovative Medicines Accelerator; the first, led by Stanford’s Nathanael Gray and targeting Parkinson’s disease, followed the same research-funding-plus-option structure. The IPF program is designed to expand Simcere’s respiratory pipeline alongside its established focus areas in neuroscience, oncology, and autoimmune disease, and extends the Accelerator’s track record of translating academic chemical biology into industry-partnered drug candidates, as demonstrated by its 2023 collaboration with Intonation Research Laboratories on neuroendocrine tumor targets. In the approved IPF space, Boehringer Ingelheim’s Ofev (nintedanib) and Roche’s Esbriet (pirfenidone) remain the standard-of-care options, neither of which reverses fibrosis, sustaining demand for mechanistically differentiated candidates.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/